![](/imager/uploads/Companies/Planet/52284/planet-blog_6439e647a38ed5b4d852739476ebaac9.webp)
![](/imager/uploads/Companies/Cofactor-Genomics/40924/40A8713_6439e647a38ed5b4d852739476ebaac9.webp)
![](/uploads/logos/_logo_h/cofactor_logo_black.png)
Fewer than 20 percent of cancer patients respond to immunotherapy; if clinicians knew which patients would respond to which therapies, they could make far more precise recommendations. Cofactor Genomics found 40 genes that make up each patient’s core immune profile. Using machine learning to analyze multiple RNA biomarkers in solid tumor tissue, the company can tell which patients with conditions such head and neck squamous cell carcinoma, non-small-cell lung cancer, colorectal cancer, or urothelial carcinoma have actionable mutations that will likely respond to modern immunotherapies.
News & Insights
![](/imager/uploads/Companies/Planet/52284/planet-blog_6439e647a38ed5b4d852739476ebaac9.webp)
Explore Companies
![](/imager/uploads/logos/58681/Avicenna_logo_black_117378e58441a39758ec294c229f7090.webp)
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
![](/imager/uploads/logos/58643/latus-logo-copy_117378e58441a39758ec294c229f7090.webp)
![](/imager/uploads/Companies/Latus/58650/Latus-lab_6439e647a38ed5b4d852739476ebaac9.webp)
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
![](/imager/uploads/logos/57002/radionetics-logo_black_117378e58441a39758ec294c229f7090.webp)
![](/imager/uploads/Companies/Radionetics/57003/Radionetics_6439e647a38ed5b4d852739476ebaac9.webp)
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
![](/imager/uploads/logos/55895/DVLP-logo-black_117378e58441a39758ec294c229f7090.webp)
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing